Alembic Pharmaceuticals Profile
Key Indicators
- Authorised Capital ₹ 40.50 Cr
- Paid Up Capital ₹ 39.31 Cr
- Company Age 14 Year, 8 Months
- Last Filing with ROC 31 Mar 2024
- Open Charges ₹ 600.00 Cr
- Satisfied Charges ₹ 219.36 Cr
- Revenue Growth 1.30%
- Profit Growth -36.21%
- Ebitda -26.90%
- Net Worth -16.56%
- Total Assets -13.34%
About Alembic Pharmaceuticals
Alembic Pharmaceuticals Limited (APL) is a leading Public Limited Indian Non-Government Company incorporated in India on 16 June 2010 and has a history of 14 years and eight months. Its registered office is in Vadodara, Gujarat, India.
It is listed on the Bombay Stock Exchange(BSE) under the ticker symbol 533573 and on the National Stock Exchange(NSE) under APLLTD.
The Corporate was formerly known as Alembic Pharma Limited. The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 40.50 Cr and a paid-up capital of Rs 39.31 Cr.
The company currently has active open charges totaling ₹600.00 Cr. The company has closed loans amounting to ₹219.36 Cr, as per Ministry of Corporate Affairs (MCA) records.
The Key Managerial Personnel (KMP) at Alembic Pharmaceuticals Limited India are Chirayu Amin as Ceo, R Baheti as Cfo, and Manisha Kathed as Company Secretary. Archana Hingorani, Manish Kejriwal, Chirayu Amin, and Five other members serve as directors at the Company.
Company Details
- Location
Vadodara, Gujarat, India
- Telephone
+91-XXXXXXXXXX
- Email Address
- Website
- Social Media
Corporate Identity Details
Industry
What products or services does Alembic Pharmaceuticals Limited offer?
Alembic Pharmaceuticals Limited offers a wide range of products and services, including Women Care, Mother Care, Health Conditions, Fever, Hair Care, Hair Growth for Men, Vitamins & Supplements, Mineral Supplements, Specialty Supplements, Probiotics.
Who are the key members and board of directors at Alembic Pharmaceuticals?
Executive Team (5)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Pranav Amin  | Managing Director | 31-Mar-2011 | Current |
| Chirayu Amin | CEO | 27-Apr-2016 | Current |
| R Baheti | CFO | 28-Jul-2014 | Current |
| Manisha Kathed | Company Secretary | 01-Apr-2023 | Current |
| Shaunak Amin | Managing Director | 02-May-2013 | Current |
Board Members (6)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
| Manish Kejriwal | Director | 31-Mar-2024 | Current |
| Ashok Barat | Director | 10-Feb-2022 | Current |
| Archana Hingorani | Director | 04-Feb-2015 | Current |
| Chirayu Amin | Whole-Time Director and Ceo | 16-Jun-2010 | Current |
| Jai Diwanji | Director | 05-May-2023 | Current |
| Rajkumar Baheti | Cfo and Whole-Time Director | 16-Jun-2010 | Current |
Financial Performance of Alembic Pharmaceuticals.
Alembic Pharmaceuticals Limited, for the financial year ended 2023, experienced modest growth in revenue, with a 1.3% increase. The company also saw a substantial fall in profitability, with a 36.21% decrease in profit. The company's net worth observed a substantial decline by a decrease of 16.56%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Alembic Pharmaceuticals?
In 2023, Alembic Pharmaceuticals had a promoter holding of 69.61% and a public holding of 30.40%. The company had 1 Associate company. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Shreno LimitedChirayu Amin and Shaunak Amin are mutual person
Onward Technologies LimitedJai Diwanji is a mutual person
Mahindra Accelo LimitedAshok Barat is a mutual person
Huhtamaki India LimitedAshok Barat is a mutual person
Sbi Mutual Fund Trustee Company Private LimitedArchana Hingorani is a mutual person
Paushak LimitedChirayu Amin is a mutual person
Charges (Loans)
₹600.00 Cr
₹219.36 Cr
Charges Breakdown by Lending Institutions
- Others : 600.00 Cr
Latest Charge Details
| Date | Lender | Amount | Status |
|---|---|---|---|
| 30 Jun 2011 | Others | ₹600.00 Cr | Open |
| 19 Nov 2021 | Hdfc Bank Limited | ₹5.00 Cr | Satisfied |
| 26 Jul 2021 | Yes Bank Limited | ₹10.00 Cr | Satisfied |
| 08 May 2014 | Bank Of Baroda | ₹1.36 Cr | Satisfied |
| 02 Dec 2011 | Dbs Bank Limited | ₹78.00 Cr | Satisfied |
How Many Employees Work at Alembic Pharmaceuticals?
Alembic Pharmaceuticals has a workforce of 15822 employees as of Feb 11, 2025. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Alembic Pharmaceuticals, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Alembic Pharmaceuticals's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
